Zymeworks ZYME Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$102.66M+9.7% | -$81.13M+33.9% | -$63.43M+44.2% | -$73.68M+34.5% | -$113.68M+9.8% | ||
| $3.65M-11.1% | $3.67M-12.4% | $3.77M-20.3% | $3.9M-36.0% | $4.11M-40.8% | ||
| $28.57M+38.4% | $28.03M+57.6% | $24.21M+50.0% | $21.96M+62.4% | $20.64M+121% | ||
| $845K+365% | -$945K-36.8% | -$662K-147% | -$628K-157% | -$319K-140% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$14.45M— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$21.42M— | -$23.17M— | —— | —— | —— | ||
| -$60K+96.5% | -$45K+97.3% | -$1.06M-185% | -$1.83M-336% | -$1.73M-270% | ||
| $2.62M-51.7% | $4.06M-9.8% | $5.87M+85.4% | $6.21M+117% | $5.41M+98.6% | ||
| $4.39M+64.5% | $3.39M+34.9% | $3.15M+6.5% | $2.77M-52.1% | $2.67M-62.2% | ||
| -$75.32M+0.6% | -$33.01M+70.0% | -$64.26M— | -$38.72M— | -$75.79M— | ||
| $1.72M-5.5% | $1.52M-23.6% | $1.25M-38.3% | $1.74M-15.6% | $1.82M-19.8% | ||
| $509K-45.2% | $831K-22.7% | $692K-72.0% | $795K-69.1% | $928K-55.2% | ||
| $84.44M— | $26.66M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $7.95M+918% | $0— | $10.08M— | $2.16M— | -$971K— | ||
| $158.91M+848% | -$18.56M+9.2% | -$8.46M-122% | -$20.98M-138% | -$21.25M-126% | ||
| —— | —— | —— | $35K— | $185K— | ||
| $168.08M— | -$24.95M— | -$57.52M— | —— | —— | ||
| $1.21M-66.1% | $1.35M-57.5% | $4.21M+1,562% | $3.66M+1,840% | $3.57M+2,782% | ||
| —— | —— | —— | —— | —— | ||
| $2.62M-51.7% | $4.06M-9.8% | $5.87M+85.4% | $6.21M+117% | $5.41M+98.6% | ||
| $3.65M-11.1% | $3.67M-12.4% | $3.77M-20.3% | $3.9M-36.0% | $4.11M-40.8% | ||
| —— | —— | —— | $215K— | $1.16M— | ||
| $845K+365% | -$945K-36.8% | -$662K-147% | -$628K-157% | -$319K-140% | ||
| -$3.53M+56.3% | -$3.34M+59.8% | -$3.29M+61.6% | -$3.15M+64.2% | -$8.09M-109% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.39M+64.5% | $3.39M+34.9% | $3.15M+6.5% | $2.77M-52.1% | $2.67M-62.2% | ||
| $509K-45.2% | $831K-22.7% | $692K-72.0% | $795K-69.1% | $928K-55.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $24.85M+215% | $16.9M+90.9% | $10.86M+22.9% | $8.14M+63.6% | $7.89M+50.7% | ||
| —— | —— | —— | —— | —— | ||
| $1.68M+19.1% | $2.44M+279% | $2.44M+50.6% | $1.67M+10.8% | $1.41M-25.8% | ||
| $1.21M-66.1% | $1.35M-57.5% | $4.21M+1,562% | $3.66M+1,840% | $3.57M+2,782% | ||
| -$77.04M+0.7% | -$34.53M+69.2% | -$65.51M— | -$40.47M— | -$77.61M— | ||
| -$77.04M+0.7% | -$34.53M+69.2% | -$65.51M— | -$40.47M— | -$77.61M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Zymeworks generate?
- Zymeworks (ZYME) generated -$75.3M in operating cash flow over the trailing twelve months.
- What is Zymeworks's free cash flow?
- After $1.7M of capital expenditures, Zymeworks's free cash flow was -$77.0M over the trailing twelve months, up 0.7% year over year.
- Where does Zymeworks's cash flow data come from?
- Every line is extracted from Zymeworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
